Search - tctmd.com

Displaying 41 - 60 of 455

Sort: Relevancy | Date

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Jamil Abdalla Saad

October 30, 2016

Presentation TCT 2016

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Josep Rodés-Cabau

October 30, 2016

Presentation TCT 2016

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Yat-Yin Lam

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Horst Sievert

October 30, 2016

Presentation TCT 2016

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Apostolos Tzikas

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Presenter: Matthew J. Price, Jason H. Rogers, Petr Neuzil

October 30, 2016

Presentation TCT 2016

Cases #5 and #6: Sheath Selection, Orientation, and Lobe Position to Optimize Occluder Deployment

Presenter: Matthew J. Price, Jason H. Rogers, Ramon Quesada

October 30, 2016

Presentation TCT 2016

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

Presenter: Matthew J. Price, Jason H. Rogers

October 30, 2016

Advertisement

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Cases #5 and #6: Sheath Selection, Orientation, and Lobe Position to Optimize Occluder Deployment

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content